Identify and evaluate new biological markers of therapeutic efficacy in chronic Chagas disease.
current phase of drug development
updated 1 Mar 2022
There is no single reliable test of cure that can be used to monitor the efficacy of a treatment in chronic Chagas disease patients in a timely manner. The lack of validated early markers of serological cure poses a significant hurdle for the development and regulatory approval of new drugs. Current work is focused on raising awareness among Chagas stakeholders about the need for biomarkers, with particular emphasis on regulatory aspects and the biomarker development process. The potential of the MultiCruzi assay is being further refined and assessed in adults for its ability to predict cure quicker than conventional serology.
The analysis of a multicentre study carried out by NHEPACHA, an Ibero-American network of researchers working on Chagas, highlighted the need for further studies to identify more appropriate tools for early assessment of therapeutic outcomes in Chagas disease.
News & resources
- 3 October 2022 - Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure, PLOS Neglected Tropical Diseases
- 12 November 2012 - USD 3 Million Awarded to Find Biomarkers for Potential Test of Cure for Chagas Disease
Get our latest news, personal stories, research articles, and job opportunities.